TargetMol

OT-551

Product Code:
 
TAR-T28273
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28273-5mg5mg£603.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28273-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28273-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
OT-551, a NF-κB inhibitor, is used potentially for the treatment of cataracts and age-related macular degeneration.
CAS:
627085-11-4
Formula:
C13H23NO3
Molecular Weight:
241.331
Purity:
0.98
SMILES:
CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1

References

1. Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, Cukras C, Chew EY, Sadda SR, Ferris FL. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6131-9. doi: 10.1167/iovs.10-5637. PubMed PMID: 20574018; PubMed Central PMCID: PMC3055748. 2. Tanito M, Li F, Anderson RE. Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats. Exp Eye Res. 2010 Jul;91(1):111-4. doi: 10.1016/j.exer.2010.04.012. PubMed PMID: 20434439; PubMed Central PMCID: PMC3175818. 3. Zarling JA, Brunt VE, Vallerga AK, Li W, Tao A, Zarling DA, Minson CT. Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. doi: 10.3389/fgene.2015.00325. Review. PubMed PMID: 26594225; PubMed Central PMCID: PMC4635221. 4. Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1900-5. PubMed PMID: 17389526.